Top

Annals of Nuclear Medicine

Published in:

22-03-2023 | Prostate Cancer | Original Article

Quantitative assessment of ^99mTc-methylene diphosphonate bone SPECT/CT for assessing bone metastatic burden and its prognostic value in patients with castration-resistant prostate cancers: initial results in a single-center retrospective study

Authors: Takashi Oya, Yasutaka Ichikawa, Satsohi Nakamura, Yoya Tomita, Takeshi Sasaki, Takahiro Inoue, Hajime Sakuma

Published in: Annals of Nuclear Medicine | Issue 6/2023

Abstract

Purpose

To evaluate the prognostic value of the quantitative assessment of ^99mTc-methylene diphosphonate (^99mTc-MDP) bone SPECT/CT in castration-resistant prostate cancer (CRPC) patients with bone metastases.

Methods

A total of 103 patients who underwent ^99mTc-MDP bone SPECT/CT imaging from the neck to the proximal femur were included. First, in 65 patients without bone metastases, the normal range of standardized uptake value (SUV) of non-pathological bone was evaluated to determine an SUV threshold to reliably exclude most normal osseous activity. Then, in 38 CRPC patients with bone metastases, lesion uptake volume (LUV), which is the extracted volume of bone metastases exhibiting high accumulation above the SUV threshold, was calculated. The relation between LUV and prostate-related mortality was statistically evaluated.

Results

Based on the SUV measurements of non-pathological bones, the optimal SUV threshold, which defines abnormal bone SPECT uptake, was determined to be 8. Median LUV was 39 mL (interquartile range 4.0–104.3 mL) in the CRPC subjects with bone metastases. Kaplan–Meier survival analysis showed a significant relation between prostate cancer-specific survival and LUV (cut-off value, 19.95 mL; P = 0.001). Multivariate analysis revealed LUV as an independent prognostic factor for the survival (P = 0.008, hazard ratio 23.424). Global chi-square test showed that LUV had significant incremental prognostic value in addition to prostate-specific antigen and the interval from progression to CRPC until bone SPECT/CT (P = 0.022).

Conclusion

Quantitative assessment of ^99mTc-MDP bone SPECT images can provide valuable prognostic information in CRPC patients with bone metastases.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578–83. https://doi.org/10.1053/hp.2000.6698.CrossRefPubMed

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33. https://doi.org/10.1056/NEJMoa1405095.CrossRefPubMedPubMedCentral

Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol. 2011;8:357–68. https://doi.org/10.1038/nrclinonc.2011.67.CrossRefPubMed

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. https://doi.org/10.1056/NEJMoa040720.CrossRefPubMed

Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61:195–202. https://doi.org/10.1002/1097-0142(19880101)61:1%3c195::aid-cncr2820610133%3e3.0.co;2-y.CrossRefPubMed

Mitsui Y, Shiina H, Yamamoto Y, Haramoto M, Arichi N, Yasumoto H, et al. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int. 2012;110:E628–34. https://doi.org/10.1111/j.1464-410X.2012.11355.x.CrossRefPubMed

Miyoshi Y, Yoneyama S, Kawahara T, Hattori Y, Teranishi J, Kondo K, et al. Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases. BMC Cancer. 2016;16:128. https://doi.org/10.1186/s12885-016-2176-6.CrossRefPubMedPubMedCentral

Poulsen MH, Rasmussen J, Edenbrandt L, Høilund-Carlsen PF, Gerke O, Johansen A, et al. Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer. BJU Int. 2016;117:748–53. https://doi.org/10.1111/bju.13160.CrossRefPubMed

10.

Utsunomiya D, Shiraishi S, Imuta M, Tomiguchi S, Kawanaka K, Morishita S, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology. 2006;238:264–71. https://doi.org/10.1148/radiol.2373041358.CrossRefPubMed

11.

Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Türler A, et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2014;41:59–67. https://doi.org/10.1007/s00259-013-2532-6.CrossRefPubMed

12.

Cachovan M, Vija AH, Hornegger J, Kuwert T. Quantification of ^99mTc-DPD concentration in the lumbar spine with SPECT/CT. EJNMMI Res. 2013;3:45. https://doi.org/10.1186/2191-219x-3-45.CrossRefPubMedPubMedCentral

13.

Kaneta T, Ogawa M, Daisaki H, Nawata S, Yoshida K, Inoue T. SUV measurement of normal vertebrae using SPECT/CT with Tc-99m methylene diphosphonate. Am J Nucl Med Mol Imaging. 2016;6:262–8.PubMedPubMedCentral

14.

Yamane T, Fukushima K, Shirotake S, Nishimoto K, Okabe T, Oyama M, et al. Test-retest repeatability of quantitative bone SPECT/CT. Ann Nucl Med. 2021;35:338–46. https://doi.org/10.1007/s12149-020-01568-2.CrossRefPubMed

15.

Qi N, Meng Q, You Z, Chen H, Shou Y, Zhao J. Standardized uptake values of (99m)Tc-MDP in normal vertebrae assessed using quantitative SPECT/CT for differentiation diagnosis of benign and malignant bone lesions. BMC Med Imaging. 2021;21:39. https://doi.org/10.1186/s12880-021-00569-5.CrossRefPubMedPubMedCentral

16.

Tabotta F, Jreige M, Schaefer N, Becce F, Prior JO, Nicod LM. Quantitative bone SPECT/CT: high specificity for identification of prostate cancer bone metastases. BMC Musculoskelet Disord. 2019;20:619. https://doi.org/10.1186/s12891-019-3001-6.CrossRefPubMedPubMedCentral

17.

Rohren EM, Etchebehere EC, Araujo JC, Hobbs BP, Swanston NM, Everding M, et al. Determination of skeletal tumor burden on 18F-fluoride PET/CT. J Nucl Med. 2015;56:1507–12. https://doi.org/10.2967/jnumed.115.156026.CrossRefPubMed

18.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79. https://doi.org/10.1016/j.eururo.2013.11.002.CrossRefPubMed

19.

Koizumi M, Wagatsuma K, Miyaji N, Murata T, Miwa K, Takiguchi T, et al. Evaluation of a computer-assisted diagnosis system, BONENAVI version 2, for bone scintigraphy in cancer patients in a routine clinical setting. Ann Nucl Med. 2015;29:138–48. https://doi.org/10.1007/s12149-014-0921-y.CrossRefPubMed

20.

Contal C, O’Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal. 1999;30:253–70. https://doi.org/10.1016/S0167-9473(98)00096-6.CrossRef

21.

Zhang Y, Li B, Yu H, Song J, Zhou Y, Shi H. The value of skeletal standardized uptake values obtained by quantitative single-photon emission computed tomography-computed tomography in differential diagnosis of bone metastases. Nucl Med Commun. 2021;42:63–7. https://doi.org/10.1097/mnm.0000000000001311.CrossRefPubMed

22.

Dittmann H, Kaltenbach S, Weissinger M, Fiz F, Martus P, Pritzkow M, et al. The prognostic value of quantitative bone SPECT/CT before (223)Ra treatment in metastatic castration-resistant prostate cancer. J Nucl Med. 2021;62:48–54. https://doi.org/10.2967/jnumed.119.240408.CrossRefPubMed

23.

Bastawrous S, Bhargava P, Behnia F, Djang DS, Haseley DR. Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice. Radiographics. 2014;34:1295–316. https://doi.org/10.1148/rg.345130061.CrossRefPubMed

24.

Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402–18. https://doi.org/10.1200/jco.2015.64.2702.CrossRefPubMedPubMedCentral

25.

Machidori A, Shiota M, Kobayashi S, Matsumoto T, Monji K, Kashiwagi E, et al. Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors. Urol Oncol. 2021;39:365.e1-.e7. https://doi.org/10.1016/j.urolonc.2020.09.036.CrossRefPubMed

26.

Thurner EM, Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, et al. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy. Eur J Cancer. 2015;51:610–9. https://doi.org/10.1016/j.ejca.2015.01.002.CrossRefPubMed

27.

Yamada Y, Sakamoto S, Rii J, Yamamoto S, Kamada S, Imamura Y, et al. Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer. Prostate. 2020;80:559–69. https://doi.org/10.1002/pros.23969.CrossRefPubMed

Title: Quantitative assessment of 99mTc-methylene diphosphonate bone SPECT/CT for assessing bone metastatic burden and its prognostic value in patients with castration-resistant prostate cancers: initial results in a single-center retrospective study
Authors: Takashi Oya
Yasutaka Ichikawa
Satsohi Nakamura
Yoya Tomita
Takeshi Sasaki
Takahiro Inoue
Hajime Sakuma
Publication date: 22-03-2023
Publisher: Springer Nature Singapore
Keywords: Prostate Cancer
Computed Tomography
Metastasis
Computed Tomography
Prostate Cancer
Scintigraphy
Bone Metastasis
Published in: Annals of Nuclear Medicine / Issue 6/2023
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-023-01833-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Quantitative assessment of ^99mTc-methylene diphosphonate bone SPECT/CT for assessing bone metastatic burden and its prognostic value in patients with castration-resistant prostate cancers: initial results in a single-center retrospective study

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2023

A preliminary study of dobutamine myocardial flow reserve on 99mTc-Sestamibi CZT-SPECT

Long-term effects of radioiodine treatment on thyroid functions and ultrasonographic features in patients with toxic adenoma and toxic multinodular goitre

The role of 18F-FDG PET/CT in primary cutaneous lymphoma: an educational review

J-ACCESS investigation and nuclear cardiology in Japan: implications for heart failure